Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Indian Journal of Hematology and Blood Transfusion
Published in: Indian Journal of Hematology and Blood Transfusion 3/2018

01-07-2018 | Short Communication

Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data

Authors: Uday Yanamandra, Parathan Karunakaran, Alka Khadwal, Gaurav Prakash, Deepesh Lad, Shano Naseem, Neelam Varma, Arunaloke Chakrabarti, Subhash Varma, Pankaj Malhotra

Published in: Indian Journal of Hematology and Blood Transfusion | Issue 3/2018

Login to get access

Abstract

Invasive fungal infection (IFI) in patients with acute promyelocytic leukemia (APL) is a common phenomenon in developing countries. In a systematic study (Dual Inducing Differentiating agents—Indian Trial: DID-IT) using dual differentiating agents (ATO and ATRA) in 98 APL patients at our center we report 18.3% incidence of IFI (n-18). Among all cases of IFI three were definitive, 14 were probable and one was possible IFI. We conclude that incidence of IFI in APL is affected by environmental and therapy related factors and mere usage of dual differentiating agents need not necessarily decrease the incidence of fungal infections.
Literature
1.
Malhotra P, Varma N, Arora N, Das R, Nath A, Patel FD et al (2010) Treatment of therapy related acute promyelocytic leukemia with the combination of all trans retinoic acid and arsenic trioxide without chemotherapy: a series of three patients. Leuk Lymphoma 51(5):933–936CrossRefPubMed
2.
Varma S, Yanamandra U, Khadwal A, Prakash G, Suri V, Kumari S et al (2015) High risk Apml treated successfully with four cycles of ATO and ATRA combination in resource constrained settings. Blood 126(23):3322
3.
Kakkar N, Bharani V, Gupta O, Shrestha D, Das A, Varma SC (2015) Respiratory distress in acute promyelocytic leukemia after ATRA therapy: not always due to differentiation syndrome. Clinicopathological conference report—PM25443. J Postgrad Med Edu Res 49(2):94–100. doi:10.​5005/​jp-journals-10028-1155 CrossRef
4.
De Pauw B, Walsh TJ, Donnelly JP, Stevens DA, Edwards JE, Calandra T et al (2008) Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 46(12):1813–1821CrossRefPubMedPubMedCentral
5.
Jain A, Prakash G, Singh C et al (2017) Analysis of clinical profile and outcome of tuberculosis in patients with acute leukemia. Indian J Hematol Blood Transfus. doi:10.​1007/​s12288-017-0875-z
6.
Ghavamzadeh A, Alimoghaddam K, Rostami S, Ghaffari SH, Jahani M, Iravani M et al (2011) Phase II study of single-agent arsenic trioxide for the front-line therapy of acute promyelocytic leukemia. J Clin Oncol 29(20):2753–2757CrossRefPubMed
7.
Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JH, Ogden A et al (2000) Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome. Blood 95(1):90–95PubMed
8.
Pagano L, Stamouli M, Tumbarello M, Verga L, Candoni A, Cattaneo C et al (2015) Risk of invasive fungal infection in patients affected by acute promyelocytic leukaemia. A report by the SEIFEM-D registry. Br J Haematol 170(3):434–439CrossRefPubMed
9.
Sharma SK, Kumar S, Singh AK, Seth T, Mishra P, Mahapatra M et al (2013) Feasibility and outcome of CT-guided lung biopsy in patients with hematological diseases and suspected fungal pneumonia. J Infect Dev Ctries 7(10):748–752CrossRefPubMed
Metadata
Title
Invasive Fungal Infections in Acute Promyelocytic Leukemia on Dual Differentiating Agents: Real World Data
Authors
Uday Yanamandra
Parathan Karunakaran
Alka Khadwal
Gaurav Prakash
Deepesh Lad
Shano Naseem
Neelam Varma
Arunaloke Chakrabarti
Subhash Varma
Pankaj Malhotra
Publication date
01-07-2018
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2018
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0894-9

Other articles of this Issue 3/2018

Indian Journal of Hematology and Blood Transfusion 3/2018 Go to the issue

Original Article

Effect of Nitric Oxide Donor on Metabolism of Apheresis Platelets

Original Article

The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis

Correspondence

Clinical Malaria as a Rare post Blood Donation Complication

Original Article

Vitamin D Deficiency and Its Association with Inflammatory Markers, Lipid Profile and Regulatory T-cells in Pediatric Sickle Cell Disease Patients

Editorial

Lymphoma in ‘India’ at the Dawn of Targeted Therapies

Short Communication

DI*A and DI*B Allele Frequencies Among Southern Thai Blood Donors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits